Alisertib
Aurora kinase A inhibitor
| Alisertib | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | 1028486-01-2 |
| PubChem | 25141694 |
| DrugBank | DB11745 |
| ChemSpider | 25071435 |
| KEGG | D09950 |
Alisertib is a small molecule inhibitor of aurora kinase A, a protein that plays a critical role in cell division by controlling the mitotic spindle apparatus. It is being investigated for its potential use in the treatment of various types of cancer, including hematologic malignancies and solid tumors.
Mechanism of Action[edit | edit source]
Alisertib selectively inhibits aurora kinase A, which is essential for the proper alignment and segregation of chromosomes during mitosis. By inhibiting this kinase, alisertib disrupts the normal progression of the cell cycle, leading to apoptosis or programmed cell death in rapidly dividing cancer cells. This makes it a promising candidate for targeting cancers that exhibit high levels of aurora kinase A activity.
Clinical Development[edit | edit source]
Alisertib has been evaluated in several clinical trials for its efficacy and safety in treating different types of cancer. It has shown potential in treating non-Hodgkin lymphoma, acute myeloid leukemia, and breast cancer, among others. The drug is typically administered orally and has been studied both as a monotherapy and in combination with other anticancer agents.
Side Effects[edit | edit source]
The most common side effects associated with alisertib include neutropenia, anemia, thrombocytopenia, and gastrointestinal symptoms such as nausea and diarrhea. These side effects are consistent with the drug's mechanism of action, as it targets rapidly dividing cells, including those in the bone marrow and gastrointestinal tract.
Research and Future Directions[edit | edit source]
Ongoing research is focused on identifying biomarkers that can predict response to alisertib, optimizing dosing regimens, and exploring its use in combination with other targeted therapies. The development of resistance to aurora kinase inhibitors is also an area of active investigation, with efforts aimed at understanding the underlying mechanisms and developing strategies to overcome resistance.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
